Myeloproliferative Neoplasms News & Features
Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.
Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.
Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status
Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.
Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.
Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
Researchers assessed outcomes for 587 patients with PV to determine the risk factors most likely to predict arterial or venous thrombosis in this patient population.
High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids
In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.
Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera
Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers
What is the concern behind PARP inhibitors and leukemia?
Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
Sign Up for Free e-newsletters
ONA Articles
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- Combined Digital Screening Best for Detecting Breast Cancers
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Seeking Reliable Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- The Efficacy and Tolerance of High Pressure Oxygen Combined With Chemotherapy in Postoperative Patients With Advanced Gastric Cancer
- Hepatocellular Cancer Pain: Impact and Management Challenges
- Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |